Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.
<a href="https://news.google.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?oc=5" target="_blank">Phenotypic and Functional Characterization of CAR-T Cells to Support Robust Cell Therapy Research</a>&nbsp;&nbsp;<font color="#6f6f6f">Labroots</font>
When will 2027’s Social Security COLA be announced?
Benfica tem 'roupa nova' para receber o V. Guimarães: o onze provável
Trump announces partial ceasefire in Ukraine war as Zelenskyy says deal is ‘news to me’
James McAtee: How Oliver Glasner has transformed Nottingham Forest midfielder from forgotten man to his new Adam Wharton
Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5EQVpBR0ZlbzluMmJ6eDBaSUlXOFRrWG1qSXR0a3oxT1NrUElONVV2WFk2LURZeVNGMk9PMVVENWRnRXRNY1cycE1hanVzdzlPVndGbFYyV3VGaTZIUXhv?oc=5" target="_blank">Characterization of CAR-T cell factors that contribute to myeloid cell activation</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNdEtLalZVaWFBeGRucFFJZm4wZ0dlUlhlWVdtYjdDcnhGbFpDeDZiLW1JQU1MRmtJUkpBZ1c3NURTSUxiSzVFU3B4UmxLaWpfRURNWEVzT1JmbTlrQmt5VkhmRG1MNGtTM3ZoVWduRVdjcEJxNTNrOW9xcVZDQjNHeWZuYi1mWWtWM042c18wbkkxWURzYVZqZU9hSDcxM1ZGWHdBS01JT1YwY3NVNldIU1dMcVQzd2JJ?oc=5" target="_blank">Single-Cell Analysis Reveals Hidden CAR T Manufacturing Risks</a>&nbsp;&nbsp;<font color="#6f6f6f">The Medicine Maker</font>
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPWlAtMmRyUmJoaENPWDR6TXJHSDJqY1oyUFIzdEpBMWsybXNHM21EMkRJX09EakQ2aUpHdU9xZW4zNG5aRHRmenBhMVdPMUkwcHBVZFZ0dUZYTG54TzROSUJocktWZWNTVWdlWF92MHNzUndnMVAzQjBOcWM5cTczRi1tY2FCTmw2eHh6Q2lR?oc=5" target="_blank">Navigating CAR-T translation in Australia: lessons from an academic program</a>&nbsp;&nbsp;<font color="#6f6f6f">Frontiers</font>
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOZkFtX2d3NG5OSHJMV1Zhak9UVnk2bWZzQTA1VndGU0xQeGJXTDRXOC1EbzhJRXlTdG1Tck9GRU45M1l2ZHVwUEdveXVacFlpRFhVUFFKbTBlOXREVm5PNGV0VC1SM1JJRy1vMy1oOEt3Q0JXd2FFTkx0dkpyaW82ODkxUzktcnFON1FnaVk3SldlclFEVFhUOEktUGFFOWxxUFRVeHhodjI?oc=5" target="_blank">New Cytometry Technique for Characterizing Viral Vectors</a>&nbsp;&nbsp;<font color="#6f6f6f">Genetic Engineering and Biotechnology News</font>
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxPbUZpOHRfMms0aFhCdFllcTkxOEJNbnRjTlU5RHN2MjJoNHgtNmsxdVhKeVRlQ2dhSlhMU05xU1dfTS1tUkQzdVN4M2hsVTlGQ0JfSzMxYkhXZUEwUGhtc2ZUYmFUeWx3azJuTTA0ZnFkOUFBODR1Zzd2WW9pWEhZSUowSURKUWlkZ3ZibzV4d2c1SE96dVlnREJ2NzNLSUY1WWprWXVfU0d6cjZmcUVPcGtrUV94Y2tfMktWYUJLemltWlhDZi1aOFc2bWJELXMzdEo2WWV6WmgxSTZQOUk0RlBZdzFCZw?oc=5" target="_blank">Single-Cell Multiomics Enables High-Resolution Vector Copy Number Profiling in CAR-T Therapies</a>&nbsp;&nbsp;<font color="#6f6f6f">Business Wire</font>
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE00eWxZVkZZSXBDUFhHZ1A0ZE9hWG1VeFpJM1RNT2ZqbDgyVXNlaUF1WmJoUDdYb0pEREJ4b0VIUmJ3OXZzWkJNQ29yeTkyTFRiNC1vb2Q3R3UxUEdnUTJ3MC1qZEVOSnJQdFN3YVVn?oc=5" target="_blank">Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility</a>&nbsp;&nbsp;<font color="#6f6f6f">Wiley Online Library</font>
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPcTV4bWVwOG5Yd3drM2tsaDN2S0NlQ0s1QUJYU016Y3JoVHAyVlFsVUZwbmNLRlRrSGZWQ1ZMSWF3TkdOMV80QS11QkxiMlhZSnU3SExOb3pIV1ptUXBtYlZUTVBBQzJKUDBBS3JUaXpLS3pnWDRVUU84NTRRZFhUd2wzekhpOUtRSUNQQ1llT2dmNWRBRUpCQU5sMXQtUnYxUGE2NVFmaXRBU3FpMmYxN1RHU1hsMEJCbmNXN1JiSy00MWc?oc=5" target="_blank">Setting Specifications for CAR-T Therapy According to Program Development Phase</a>&nbsp;&nbsp;<font color="#6f6f6f">BioProcess International</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9VTi13cDQzMVdDNUptMG95SzJIQmZrd1J3dVlsSnotSHpDQmtTSzAySEw1TGd5SWhFNXJDOXVMUUFNaUdGallJc1pMeVdSR3BsdzFhaUFrelEtSlN2Y0Zj?oc=5" target="_blank">Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPMG1tT2JXU2stbVZUMnVFOEpVX18tYWlaaTdPOUszQ05EWDBWSy12a0taRmMwSlMteU9MNzhlV05HTklVT2VOS3hYTWpPSEZKZlZtZXJybXE3ME5OZ3NjeHk5bWVueXBma0dpQ2FLUENIUW0tNlVTdTc4YVZUS1FpS21uOGtuMHBSWk9pVU00ZF9NSHlxQVEtVVBiWE5UajhKdEVYSFp0cDlqLWVibW04QWtDODlvakJ5VFgxTjI0UnNCRUZnOVR1ak5iRUFSQUpVSVQ5TEdqTnNoa3oycTJEeWRraEhEY0tp?oc=5" target="_blank">Transforming Cell Therapy Manufacturing With Cellular Starting Material Immunophenotyping at the Point of Collection</a>&nbsp;&nbsp;<font color="#6f6f6f">Technology Networks</font>
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQYlBoSHllQTFSb18wVW5meHB0ZnJhbEd6WkJjSnlkY1FleFpRMG5rOElueW5VZjFuSzBiR2FFeDMxSTcyb3J2b1gwTkZVOW1mRWlXSkZWWElkS3BLYXNZeUd5MzlLNlJMaVdnTUtzcm5XLU5nTjY0c0RpdHhMeXoxWVFaaEJPcllQQzNGcXR3cjFZSTU4aVRUdi16cWg0Y1d3MlRnaEtqN1JsQ1Q4SWdtT2ZleDlpN3E2bkF6Rg?oc=5" target="_blank">Addressing CAR-T Therapy Challenges in Extramedullary Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Hematology Advisor</font>
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNZ1poNUhoeFQ0ZWVIbHN5NGdFZE5QVW1ZLXRFVlhDOVM5UGJwekpvY09IUUhJRGstOEMtd05PSjY4dXFpckk4blgxZTM5RkVxTE1uaUkzemdxNXpjQVFmaENnT3BpU0N2b0gtNEVCTXBzdFQ3OEx3c2taM1p2UTFCUU9QeGgtWkVYbmNYZkpVNGZadw?oc=5" target="_blank">New insights on potency assays from recent advances and discoveries in CAR T-cell therapy</a>&nbsp;&nbsp;<font color="#6f6f6f">Frontiers</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBSZzExNTBJZzRUTWVkS3I2cjkzOXVBOXVvNzI0TnpWVzNFMjFaNzJ1cGRadkFma2p1N0RhUndVYXpYUkdpcmNHZU9EMlY2WVVaRGZka2dPazJfYjNVeWk4?oc=5" target="_blank">Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNWEdqYTlxbXFlaGt6UEx3MEluZXBwM3M5T2J3NWx4bG5CWnVmb0pySFctYnlqSFhfZ0N4M3pTYU9DSGp4WHRSNmF6YlpOaW1vLUVMUzhzZlB0YmlsNFZoWU5HR1Z4X1U2NklrMjJtQTktUk5PY0JiV1ZUY05uQkdFeFNRNHY1MjJxQWpTSFJBaVpBUQ?oc=5" target="_blank">Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer</a>&nbsp;&nbsp;<font color="#6f6f6f">Frontiers</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1tQjYzc1VGbTJSOFVBRDlDamt5cU1WcGxpdWpzOHh0cml0SmRmWjNGbmIyT05JRng5VzVZSVM1cFRoV1pqbzBqLWZTZTRQYzkydGNrQVdYUE5reG5VZEZJ?oc=5" target="_blank">-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1aWHg3NzhLZGo0Y2FZLWJ6TGpPTGt6NmRyWmNrc21oWHZmM2JRN2tGNEljYnA4RVpYbmlqNmJyanVJZ1BzY19mM0tVNHc0eVl2ckc3dWlXSlpLT2xGdl80?oc=5" target="_blank">Label-free in-line characterization of immune cell culture using quantitative phase imaging</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9OS1JxbjFZYVZyUHU5bGZRUUxmN1RZWGdPdXNTemhYU1ZReEpPMDhSelJYbWxRb3hJcUM3d2tXTXRnR01RZ2FnZko1cTVyeWNNRG1Pa1prbVlEZDZRV1Z3?oc=5" target="_blank">C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1hOTBiNy1PY0ppNDZmX292RFFRUHk2emNkeEd2bGdjNGtYNS1wd2JVSnFyd3FYcS1sN3ZVUWxJVWRRSThxbVUteDBoN21CbXZnVTgwMEZHaUstSkU0YWFv?oc=5" target="_blank">Developing a robust CAR-T-cell characterization strategy: key assays and insights</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5WWmc4bHVqc1JUZFREUVNSNlNsSWdBamxQZ29nOGkwbXdHSFh4N0xYLW1iUUZ5SE9KdjRqUS1Sa0wxZW1wYnRId0lIcXFoT180dWZxMFB3Mk9qcUR5YnNN?oc=5" target="_blank">A distinct CAR-T cell phenotype mediates therapeutic response at limited doses</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE11VTlHUFJsdEdwbThlODlUUDRMQWpnanBldlh1QWNXQ2NuSlgtTXAwbWFheDh5VzgtSk4zZDducnljTF80LTAyempjUFp5cXlPMXR4VVR0cGFOVll6Wi1n?oc=5" target="_blank">Enhancing CAR-T cell functionality in a patient-specific manner</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE1NTUhvN3E3R3JiTVBYUkY0YlJjN2tvSlRxSmFPV1c1WVlQd0xvVk9uZndxSnF0Zjh6S2JLTXBZRVMxbmJHb0NZclk1Zi1aSXlZOVJvREpmeFJaVXZtREE?oc=5" target="_blank">Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9kUnNfUFJuRXJXV3JXREtXdmVzaGpDNWRMUG9YNXl3emMzT1pZNjFlckJ2aUN3Qm8wMGpnMDN1ZlFvXy1QcDFhSzFiMHpFMlU2b3NnblNVRVotYnJwbnNj?oc=5" target="_blank">Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma | Leukemia</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1nbWRKcWl1VlBFSGNOSmc4OUVzSnNIRXd4NVFoTzY3b0xySmthQXBRd3ExVGJyTExOMTRxdXJzTHlsbEpTMFNTOFBPN1dCUHhVbjhhSmlOV2ItSnVTdzhv?oc=5" target="_blank">CAR T cells implicated in long-term leukaemia remission</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5nWjVsZWR0MHFEVENabmFIbHNZTkRmYVAtVTM0a2sxV2FEcDZKSzdGUnNrbWJvZml3SmdVLXdvV21wQUJlSTN3R0pEbU5vVVZINXpXTXljaW9YUmFEdHdV?oc=5" target="_blank">Cell trajectory modulation: rapid microfluidic biophysical profiling of CAR T cell functional phenotypes</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE0zeDBaSG93RFVoU05fZjZnVjN1d2hxd2tRV0ZMalB0dmFCTHJkblpzS2JWTGpuOHQzdUQzM2NMN1VkWm55R0VmT09RanJfOVpTd1htamhuVGNreXRkaE1Z?oc=5" target="_blank">PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxORFY2elFNNy1KTkRUQVI1cHllaHYyUkI4WVJxbmdFOGxjNDNkcy1hemM2SmdmR2JERnhxTXA5QTZ3SWNJRk5BOXZVVGc3LU92VGZDQ1RzeW5HcnJyRVkwYnFKeHAwYmF6SzFIV3ZhRWd0bmlOVlRxSmF3WkhaWl8ybUdiM1hDbzBvMTFHeDdvTS1ZYi1RUFl3Tm9IOGFxcks1b0Q2dXNPcDM?oc=5" target="_blank">Gene Expression Profiles Characterize CAR T-Cells in Solid and Hematological Tumors</a>&nbsp;&nbsp;<font color="#6f6f6f">CGTLive®</font>
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPMVJ6bkhqSnJhOERYQkJVWmx1LV81LTB0T3RRVE5vZUFxazhHWEZFem5TWmMyWFMwM3p1RzVKS0J2UzNQVEpUbU1xcHNzUVJSSlJkSWhEN3oyOTNkVXBOZlByOUhhd2RTS1doWUdHNmhxMW5tenp6NHVBZHJKeHVicUxsSk9VaXljNkFvSldwakNiTU8tT01NaHJqU0VqZHRTWWJ5OV9uV0tfWnlPUkhySlhuMmk2bVBqcG9DN183Q1FjMDl4WjVxaQ?oc=5" target="_blank">Accelerating In Vivo CAR-T Development Using Single Nanoparticle Characterization</a>&nbsp;&nbsp;<font color="#6f6f6f">Genetic Engineering and Biotechnology News</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9YSWVBdWNfdGwwNG9ZaW9BYm9ZQTYyanVveXlrcEFFeVNFODRWODlWaDVtNzhPRnhRWFItR0gtMEFIdF9UbEhCLUhyZDQ5ckRNOUs0YkJ6UTRHWEw2ektn?oc=5" target="_blank">TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5tNEZPY2RMRjBMbUNOcVFibjNYcHJ1X0pZaEtaV3p4Ync4a0JFdkFEdXN6UV9sdGl0TzJyQWoyU2x1VGN1TEpna1VscmtGTTJ2ZGRGQk9zdjdxaTFWd3FJ?oc=5" target="_blank">Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5pZTJEcVVMR0Q0TUNkWnhNRXpreEptaWkzcDdQNVZHVDlLSlRjV00xTVJQS0ZybkpVRlZ2a3NnZTJKeUhnZzBHOFpJQU9rbE5EZ3Rfd2xWb3pjVmRXdzJn?oc=5" target="_blank">A yeast surface display platform for characterizing CAR T cell responses to cancer antigens</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>